论文部分内容阅读
目的:对肺表面活性物质在足月新生儿急性呼吸窘迫综合征患者临床治疗中的应用效果进行观察。方法:临床选取我院在2013年4月-2014年5月实施治疗的68例急性呼吸窘迫征新生儿,对其均实施肺表面活性物质治疗,对患儿治疗前后的临床症状进行对比分析。结果:经过治疗,68例患儿治疗总有效64例,其总有效率为94.12%;治疗前后患儿的PaO2、PaCO2、a/AP O2、OI指标具有明显差异,对比具有统计学意义(P<0.05)。结论:足月新生儿急性呼吸窘迫综合征实施肺表面活性物质治疗,能够对患者的肺功能进行显著改善,值得推广应用。
Objective: To observe the effect of pulmonary surfactant in the clinical treatment of full-term neonatal acute respiratory distress syndrome. Methods: Sixty-eight neonates with acute respiratory distress syndrome who were treated in our hospital from April 2013 to May 2014 were enrolled in this study. All of them were treated with pulmonary surfactant, and their clinical symptoms were compared before and after treatment. Results: After treatment, the total effective rate was 94.12% in 68 children. The total effective rate of PaO2, PaCO2, a / AP O2 and OI in children before and after treatment were significantly different (P <0.05). CONCLUSIONS: Pulmonary surfactant therapy for term neonates with acute respiratory distress syndrome can significantly improve pulmonary function in patients and is worth promoting.